Literature DB >> 16961149

Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note.

Lucia Ricci-Vitiani1, Francesco Pierconti, Maria Laura Falchetti, Giovanna Petrucci, Giulio Maira, Ruggero De Maria, Luigi Maria Larocca, Roberto Pallini.   

Abstract

Permanent cell cultures are invaluable tools for understanding the biological characteristics of tumors. In the present study the authors report on the establishment of permanent human cell lines from three cases of aggressive chordomas of the clival region. All of the parental tumors showed telomerase activity. Cultured chordoma cells had a doubling time of 5 to 7 days and grew as a monolayer of cells that retained both the immunophenotype and the p53 status of the parental tumor. In vitro, chordoma cells overexpressed telomerase, supporting the hypothesis that this enzyme is required for the immortalization process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961149     DOI: 10.3171/jns.2006.105.3.482

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

2.  Characterization and analysis of human chordoma cell lines.

Authors:  Cao Yang; Francis J Hornicek; Kirkham B Wood; Joseph H Schwab; Edwin Choy; John Iafrate; Andrew Rosenberg; G Petur Nielsen; Ramnik J Xavier; Henry Mankin; Zhenfeng Duan
Journal:  Spine (Phila Pa 1976)       Date:  2010-06-01       Impact factor: 3.468

3.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Authors:  Wesley Hsu; Ahmed Mohyeldin; Sagar R Shah; Colette M ap Rhys; Lakesha F Johnson; Neda I Sedora-Roman; Thomas A Kosztowski; Ola A Awad; Edward F McCarthy; David M Loeb; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

4.  Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Authors:  Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

5.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

6.  Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.

Authors:  Salvatore Di Maio; Esther Kong; Stephen Yip; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-06-01

7.  Molecular characterization of putative chordoma cell lines.

Authors:  Silke Brüderlein; Joshua B Sommer; Paul S Meltzer; Sufeng Li; Takuya Osada; David Ng; Peter Möller; David A Alcorta; Michael J Kelley
Journal:  Sarcoma       Date:  2010-12-30

8.  Chordoma-derived cell line U-CH1-N recapitulates the biological properties of notochordal nucleus pulposus cells.

Authors:  Nobuyuki Fujita; Satoshi Suzuki; Kota Watanabe; Ken Ishii; Ryuichi Watanabe; Masayuki Shimoda; Keiyo Takubo; Takashi Tsuji; Yoshiaki Toyama; Takeshi Miyamoto; Keisuke Horiuchi; Masaya Nakamura; Morio Matsumoto
Journal:  J Orthop Res       Date:  2016-08-02       Impact factor: 3.494

9.  Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies.

Authors:  Verena Gellner; Peter Valentin Tomazic; Birgit Lohberger; Katharina Meditz; Ellen Heitzer; Michael Mokry; Wolfgang Koele; Andreas Leithner; Bernadette Liegl-Atzwanger; Beate Rinner
Journal:  Sci Rep       Date:  2016-04-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.